Exelixis (NASDAQ:EXEL) Price Target Raised to $46.00

Exelixis (NASDAQ:EXEL) had its target price hoisted by analysts at Royal Bank Of Canada from $45.00 to $46.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s target price points to a potential upside of 9.34% from the company’s current price.

Several other research firms have also commented on EXEL. Leerink Partners upgraded Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a research note on Tuesday, October 21st. Bank of America cut shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 target price on the stock. in a research note on Monday, January 5th. Citigroup downgraded Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Wolfe Research assumed coverage on Exelixis in a report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Finally, Guggenheim lowered shares of Exelixis from a “buy” rating to a “neutral” rating in a report on Monday, November 3rd. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $46.53.

Exelixis Trading Down 2.1%

Shares of NASDAQ:EXEL traded down $0.91 during midday trading on Wednesday, reaching $42.07. The company had a trading volume of 1,741,698 shares, compared to its average volume of 2,572,806. The company’s 50 day moving average price is $43.69 and its 200 day moving average price is $40.92. Exelixis has a 52-week low of $32.38 and a 52-week high of $49.62. The stock has a market cap of $11.28 billion, a P/E ratio of 17.78, a P/E/G ratio of 0.74 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. The business had revenue of $598.66 million for the quarter, compared to analyst estimates of $609.17 million. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.55 EPS. Research analysts forecast that Exelixis will post 2.04 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Patrick J. Haley sold 34,187 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $41.88, for a total transaction of $1,431,751.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 72,230 shares of company stock valued at $3,046,923 over the last three months. 2.85% of the stock is currently owned by insiders.

Institutional Trading of Exelixis

Hedge funds and other institutional investors have recently modified their holdings of the business. Richardson Financial Services Inc. lifted its position in shares of Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 292 shares in the last quarter. Anchor Investment Management LLC lifted its position in shares of Exelixis by 500.0% during the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 500 shares during the period. Root Financial Partners LLC acquired a new position in Exelixis during the third quarter worth about $28,000. Luminist Capital LLC lifted its holdings in shares of Exelixis by 2,740.0% in the second quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 685 shares in the last quarter. Finally, Activest Wealth Management purchased a new position in shares of Exelixis during the 4th quarter worth approximately $32,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q4 EPS materially beat estimates (reported $0.94 vs. ~$0.74 consensus) and operating profit/net income improved, supporting near‑term profitability and cash generation. Zacks: Q4 Earnings Beat
• Positive Sentiment: Management authorized and executed substantial buybacks (~$264.5M reported), returning capital while keeping R&D investment high — a mix that can support shareholder value and signal confidence in the pipeline. MarketBeat: Solid Earnings & Buybacks
• Positive Sentiment: Commercial momentum: the Cabometyx franchise remains the primary revenue driver (multi‑indication use), with the franchise cited at ~$2.12B and ongoing sales expansion supporting 2026 revenue guidance. MSN: Cabometyx Franchise & Growth Strategy
• Positive Sentiment: Pipeline catalyst: zanzalintinib is advancing toward regulatory review/launch plans (potential multi‑billion peak sales) — a successful approval would materially change the growth profile. Zacks: Zanzalintinib in Focus
• Neutral Sentiment: 2026 revenue guidance ($2.52–$2.62B) was reiterated but explicitly excludes potential zanzalintinib contribution — guidance gives a concrete baseline but leaves upside conditional on approval. BusinessWire: Q4 Results & Guidance
• Neutral Sentiment: Investors can review the earnings call transcript and slide deck for detail on commercialization and R&D pacing; management emphasizes a franchise strategy and continued ~ $1B R&D investment. Seeking Alpha: Earnings Call Transcript
• Negative Sentiment: Total revenue missed Street estimates (reported ~$598.7M vs. consensus ~ $609–616M), which helps explain the share pullback despite the EPS beat. QuiverQuant: Revenue Miss
• Negative Sentiment: Mixed analyst signals: some firms reiterated/raised targets but Wells Fargo’s updated Equal Weight target ($35) implies downside vs. the market price — adding near‑term pressure from cautious forecasts. TickerReport: Wells Fargo PT Raised to $35
• Negative Sentiment: Recent insider selling noted in filings (several executive sales highlighted), which can be interpreted negatively by some investors even as other insiders made purchases. QuiverQuant: Insider Activity Summary

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.